Projects Funded (All Years)

2021 Projects Funded

RNASeq “in the round”
Nicholas Foreman

Development of humanized immune system PDX model for evaluating the tumor-immune interaction in pediatric brain tumors
Nicholas Foreman, Andrea Griesinger

Single-nuclei RNA-seq characterization of the tumor microenvironment in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumors
Nicholas Foreman

Targeting BMI1 in ATRT
Rajeev Vibhakar

Targeting H3K27M-mutant DIPG tumors with novel CAR T cell therapy
Sujatha Venkataraman, Rajeev Vibhakar

To investigate the biological effects of radiation and the signaling pathways that promotes radio-resistance of DIPG
Sujatha Venkataraman, Nathan Dahl, Rajeev Vibhakar

Radiation-induced transcriptional adaptation in pediatric high-grade glioma
Nathan Dahl

Understanding the oncogenic role of BMI1 in ependymoma (EPN) PFA tumors at the single-cell transcriptional level
Sujatha Venkataraman, Andrew Donson, Nicholas Foreman, Rajeev Vibhakar

Rational approach to combined targeting of two major transcriptional regulators, EZH2 and CDK9 in MYC-medulloblastoma
Rajeev Vibhakar, Krishna Madhavan

Investigate the molecular pathways regulated by the oncogenic MIC2 in driving H3K27M-DIPG tumorigenesis
Sujatha Venkataraman, Adam Green, Ilango Balakrishnan

Epigenetic Mechanisms of Aurora Kinase Inhibition as a Rational Target in H3K27M-Mutant Diffuse Midline Glioma
Adam Green

Investigation of Components of Potential DIPG and High-Grade Glioma Combination Therapy Trials
Adam Green

Development of CD44 variant 6 targeting chimeric antigen receptor (CAR) T cells in atypical teratoid rhabdoid tumor (ATRT)
Siddhartha Mitra, Anandani Nellan

 

Development of In Utero driven Mouse Models of Diffused Midline Gliomas to Study the tumor immune interactions in Pediatric Midline Gliomas
Siddhartha Mitra, Santos Franco, Adam Green

Development of Novel Therapies for Atypical Teratoid/Rhabdoid Tumors
Jean M. Mulcahy-Levy

Low-grade glioma immune characterization
Jean M. Mulcahy-Levy, Shadi Zahedi

Advancing Characterization of Epithelial-to-Mesenchymal Transition in ACP through Phospo-kinase Analysis
Todd Hankinson

Preclinical testing of the Immunotherapeutics Nivolumab, Bevacizumab, and Adecatumumab using ex vivo Adamantinomatous Craniopharyngioma Tissue
Todd Hankinson

Intelligent System Design for Interpretable Deep Learning Modeling of Rare Pediatric Brain Tumors from a Multi-disciplinary Perspective
Todd Hankinson

Neurocognitive Function in the Pediatric Hematology-Oncology Population
Claire Fraley

Development of humanized immune system PDX model for evaluating the tumor-immune interaction in pediatric brain tumors
Nicholas Foreman

Targeting Mechanisms of Relapse upon CAR-T Failure in MLLr Leukemia
Patricia Ernst, Terry Fry

Use of ddPCR for Residual Disease Detection (including Post-Transplant) in Pediatric AML 
Amanda Winters

Development of Novel Chimeric Antigen Receptors to Target Antigen-Low Pediatric Leukemia
Mark Eric Kohler

Biomimetic Microenvironments to Model Leptomeningeal Metastasis in Pediatric Neuro-Oncology (Year 3)
Rachael Sirianni

Translating discoveries from brain tumor genomics into new therapeutic strategies 
David A. Solomon

2020 Projects Funded

RNASeq “in the round”
Nick Foreman

Creation of a single-cell atlas of pediatric brain tumors (year 2 of 2)
Nick Foreman

Pre-Clinical modeling of drug efficacy in pediatric brain tumors
Rajeev Vibhakar

High-throughput drug screening in pediatric brain tumors for rapid clinical translation
Nicholas Foreman

Rational approach to combined targeting of two major transcriptional regulators, EZH2 and CDK9 in MYC-medulloblastoma
Rajeev Vibhakar

Investigate the molecular pathways regulated by the oncogenic MIC2 in driving H3K27M-DIPG tumorigenesis
Sujatha Venkataraman

Developing a Clinically Translatable Interpretable 3D Radiographic and Transcriptomic Joint Domain Deep Learning Framework for Limited Datasets Using Adamantinomatous Craniopharyngioma as an Example
Todd Hankinson

PRMT5 Inhibition in Pediatric High-Grade Glioma
Adam Green

Development of Novel Therapies for Atypical Teratoid/Rhabdoid Tumors
Jean M. Mulcahy Levy

Development of CAR T cells to target ependymoma and the tumor microenvironment 
Anandani Nellan, Nicholas Foreman

 

Understanding the oncogenic role of BMI1 in ependymoma (EPN) PFA tumors at the single-cell transcriptional level
Sujatha Venkataraman, Andrew Donson, Nicholas Foreman, Rajeev Vibhakar

Development of Human Immune System Mouse Models of ATRTs
Siddhartha S. Mitra

Targeting Hes5 in Embryonal tumors with multilayered rosettes (ETMR)
Sujatha Venkataraman, Andrew Donson

EMT in Craniopharyngioma
Todd Hankinson

Investigation Toward a DIPG Combination Therapy Clinical Trial
Adam Green

Targeting BMI1 in AT/RT
Rajeev Vibhakar

Combinatorial Immunotherapy against High-Risk Medulloblastoma
Siddhartha S. Mitra

Tumor microenvironment (TME) Modifying Immunotherapy Combined with Tumor Neurosphere Vaccine for Pediatric High-Grade Glioma
Anandani Nellan, Adam Green, Steven Dow

Biomimetic Microenvironments to Model Leptomeningeal Metastasis in Pediatric Neuro-Oncology
Rachael Sirianni

Evaluating the Mechanism and Efficacy of Targeting the Replication Stress Pathway in Pediatric Osteosarcomas
Pankita H. Pandya

2019 Projects Funded

RNASeq “in the round”: Extension of tumor characterization to include mutational and fusion data on all new patients
Nick Foreman, Andrew Donson, Rajeev Vibhakar
Researchers will use RNA sequencing to analyze new tumors, as well as tumor samples from the last 30 years. This project will extend the analysis to identifying whether tumors result from gene mutations or fusions of existing genes. This improved characterization of tumor samples provides additional information to help determine the best treatment for each tumor.

Creation of a single-cell atlas of pediatric brain tumors
Andrew Donson, Nicholas Foreman, Todd Hankinson, Rajeev Vibhakar

High-throughput drug screening in pediatric brain tumors for rapid clinical translation
Nicholas Foreman, Katie Dorris, Andrew Donson

Pre-Clinical Modeling of drug efficacy in Pediatric Brain Tumors
Angela Pierce, Rajeev Vibhakar

High-Throughput Next Generation Sequencing and Analysis of CRISPR-Cas9 Mediated Gene Knockout Screen and Validation of Targets identified in Pediatric Brian Tumor
Sujatha Venakataraman, Rajeev Vibhakar

Targeting NTRK fusions in Diffuse Intrinsic Pontine Glioma (DIPG)
Rajeev Vibhakar, Lindsey Hoffman, Nathan Dahl

Investigation of Pediatric Treatment-Induced High-Grade Gliomas
Adam Green

Novel targeting of CD99, a cell surface protein in H3K27M-mutant DIPG
Sujatha Venkataraman, Adam Green, Siddhartha S. Mitra, Terry Fry, Rajeev Vibhakar

Using a CRISPR screen to identify genes that regulate immune surveillance by microglia and macrophages
Siddhartha S. Mitra

In vivo model targeting BMI1 in ATRT
Irina Alimova, Angela Pierce, Rajeev Vibhakar

Targeting BMI1 in neuroblastoma tumors
Sujatha Venkataraman, Rajeev Vibhakar

 

Understanding the oncogenic role of CDK7 and CDK12, the crucial targets identified from the shRNA screening in medulloblastoma
Bethany Veo, Rajeev Vibhakar

Analysis the Epigenome to identify novel resistance mechanisms to targeted BRAF inhibition
Jean Mulcahy Levy, Rajeev Vibhakar

Can ATR kinase inhibitors sensitize medulloblastoma tumor cells to radiation and chemotherapy treatments?
Rajeev Vibhakar

Predictive Diagnosis and Genomics of Pediatric Neurological Tumors via Convolutional Neural Networks
Todd C. Hankinson

Multiple-Biopsy of Infiltrative Glioma (M-BIG) Study
Nathan Dahl, Lindsey Hoffman, Adam Green

Development of a novel extracellular PRAME antibody to target atypical teratoid rhabdoid tumor
Anandani Nellan, Andrew Donson

Establishing DIPG xenograft models and advancing therapeutic strategy in DIPG
Sujatha Venkataraman, Siddhartha S. Mitra

In vivo animal model to investigate nanoparticle-mediated brain drug delivery
Krishna Madhavan, Rajeev Vibhakar

Development of Models of Recurrent Pediatric High-Grade Glioma
Adam Green

Study looking at feasibility of isolating circulating tumor DNA from blood, cerebrospinal fluid and urine in Pediatric Solid Tumor patients
Nicholas Foreman, Masanori Hayashi

Biomimetic Microenvironments to Model Leptomeningeal Metastasis in Pediatric Neuro-Oncology
Rachael Sirianni

2018 Projects Funded

The RNASeq transition: Creation of a pediatric brain tumor RNAseq reference database (year 2 of 2)
Andrew Donson, Nick Foreman, Rajeev Vibhakar

Chipping “in the round.” Extension of tumor characterization to include mutational and fusion data on all new patients
Nick Foreman, Andrew Donson, Rajeev Vibhakar

High throughput next-gen sequencing and analysis of CRISPR-Cas9 mediated gene knockout system
Sujatha Venkataraman, Rajeev Vibhakar

Pre-clinical modeling of drug efficacy in pediatric brain tumors
Angela Pierce, Rajeev Vibhakar

 

High-throughput drug screening in pediatric brain tumors for rapid clinical translation
Andrew Donson, Nick Foreman, Katie Dorris

Disease progression model for H3K27M-mutant DIPG: Determining downstream effects of effective treatment
Sujatha Venkataraman, Adam Green

The oncogenic role of the SEC in H3K27M-mutant DIPG
Nathan Dahl, Rajeev Vibhakar

Use of pluripotent stem cells (hiPSCs) to model DIPG cell formation and radio-resistance
Sujatha Venkataraman, Rajeev Vibhakar

2017 Projects Funded

Chipping “in the round.” Extension of tumor characterization to include mutational and fusion data on all new patients
Nick Foreman, Andrew Donson, Rajeev Vibhakar

The RNASeq Transition: Creation of a pediatric brain tumor RNAseq reference database (year 2 of 2)
Andrew Donson, Nick Foreman, Rajeev Vibhakar

In vivo animal model to investigate nanoparticle-mediated brain drug delivery (year 3 of 3)
Rajeev Vibhakar, Krishna Madhavan

Pre-Clinical modeling of drug efficacy in pediatric brain tumors
Angela Pierce, Rajeev Vibhakar

High-throughput drug screening in pediatric brain tumors for rapid clinical translation
Nick Foreman, Andrew Donson, Katie Dorris

Disease progression model for H3K27M-mutant DIPG: Determining Downstream Effects for Effective Treatment
Adam Green, Sujatha Venkataraman

The oncogenic role of the SEC in H3K27M-mutant DIPG
Nathan Dahl, Rajeev Vibhakar

 

High throughput NexGen Sequencing and Analysis of CRISPR-Cas9 Mediated Gene Knockout System
Sujatha Venkataraman, Rajeev Vibhakar

Analysis of paired BRAF v600e mutant glioma patient samples to identify novel resistance mechanisms to targeted BRAF inhibition
Jean Mulcahy-Levy, Theodore Nicolaides

Use of human-induced Pluripotent Stem Cells (hiPSCs) to model DIPG tumorigenesis and radio-resistance
Sujatha Venkataraman, Rajeev Vibhakar

Oncogenesis caused by loss of SMARCB1 tumor suppressor is dependent on the activity of SIRT2
Rajeev Vibhakar

To establish a new genome-editing technology called CRISPR-Cas9 as a means to generate pediatric brain tumor models carrying deletion or insertion of genes in a highly efficient manner
Sujatha Venkataraman, Rajeev Vibhakar

2016 Projects Funded

Chipping “in the round.” Extension of tumor characterization to include mutational and epigenetic profiling as well as mRNA expression (classical “chipping”)
Nick Foreman, Andrew Donson, Rajeev Vibhakar

The RNASeq Transition: Creation of a pediatric brain tumor RNAseq reference database (year 1 of 2)
Andrew Donson, Nick Foreman, Rajeev Vibhakar

In vivo animal model to investigate nanoparticle-mediated brain drug delivery (year 2 of 3)
Rajeev Vibhakar, Krishna Madhavan

To Establish a new genome-editing technology called CRISPR-Cas9 as a means to generate pediatric brain tumor models carrying deletion or insertion of genes in a highly efficient manner
Sujatha Venkataraman, Rajeev Vibhakar


Developing CAR T-Cell therapy for Pediatric Brain Tumors
Nicholas Foreman, Anadani Nellan

Cancer Stem Cell Influences in the setting of BRAF Mutations
Jean Mulcahy-Levy

Pre-Clinical Trial of Anti-Inflammatory Monoclonal Antibodies in a Mouse Model of Adamantinomatous Craniopharyngioma
Todd Hankinson, JP Barbera

Transcriptome Analysis of Recurrent Pediatric High Grade Gliomas
Adam Green

To investigate whether PTC-209, a small-molecule inhibitor of BMI-1, can potentiate DIPG cell killing by radiation: in-vitro and in-vivo study
Sujatha Venkataraman, Rajeev Vibhakar